{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Acridine_Carboxamide",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.",
    "fdaUniiCode": "0N3V8R4E13",
    "identifier": "C2203",
    "preferredName": "Acridine Carboxamide",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1968",
      "C582"
    ],
    "synonyms": [
      "ACRIDINE CARBOXAMIDE",
      "Acridine Carboxamide",
      "DACA",
      "N-(2-(Dimehtylamino)ethyl)acridine-4-carboxamide",
      "SN 22995",
      "XR5000",
      "acridine carboxamide"
    ]
  }
}